APREA THERAPEUTICS ($APRE) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.22 per share, beating estimates of -$0.23 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $APRE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
APREA THERAPEUTICS Insider Trading Activity
APREA THERAPEUTICS insiders have traded $APRE stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $APRE stock by insiders over the last 6 months:
- OREN GILAD (President/CEO) purchased 28,100 shares for an estimated $25,009
- MARC DUEY purchased 21,459 shares for an estimated $24,999
- JOHN P. HAMILL (SrVP/CFO/Prin Fin & Acct Ofcr) has made 2 purchases buying 10,700 shares for an estimated $10,898 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
APREA THERAPEUTICS Hedge Fund Activity
We have seen 10 institutional investors add shares of APREA THERAPEUTICS stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC added 645,000 shares (+174.1%) to their portfolio in Q1 2026, for an estimated $492,070
- MURCHINSON LTD. added 340,139 shares (+inf%) to their portfolio in Q4 2025, for an estimated $290,138
- DAFNA CAPITAL MANAGEMENT LLC removed 137,174 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $117,009
- DRW SECURITIES, LLC added 120,651 shares (+inf%) to their portfolio in Q4 2025, for an estimated $102,915
- SIO CAPITAL MANAGEMENT, LLC removed 112,223 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $95,726
- VANGUARD GROUP INC removed 100,152 shares (-63.3%) from their portfolio in Q4 2025, for an estimated $85,429
- CITADEL ADVISORS LLC added 51,041 shares (+inf%) to their portfolio in Q4 2025, for an estimated $43,537
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
APREA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $APRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/29/2026
To track analyst ratings and price targets for APREA THERAPEUTICS, check out Quiver Quantitative's $APRE forecast page.
APREA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $APRE recently. We have seen 3 analysts offer price targets for $APRE in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Matthew Biegler from Oppenheimer set a target price of $5.0 on 05/07/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $1.2 on 03/31/2026
- Robert Driscoll from Wedbush set a target price of $7.0 on 03/31/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
